Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS Sabbagh, M. N., Taylor, A., Galasko, D., Galvin, J. E., Goldman, J. G., Leverenz, J. B., Poston, K. L., Boeve, B. F., Irwin, D. J., Quinn, J. F. 2023; 9 (1): e12375


The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Clinical Dementia Rating scale and Alzheimer's Disease Assessment Scale-Cognitive Subscale being among the most often used instruments in AD clinical trials. In contrast, there are no validated instruments for use in clinical trials of drugs for the treatment of dementia with Lewy bodies. This poses challenges for drug development because the regulatory pathway to drug approval requires demonstrable efficacy measures. In December 2021, the Lewy Body Dementia Association advisory group met with representatives from the US Food and Drug Administration to discuss the lack of approved drugs and treatments, discernment of efficacy measures, and identification of biomarkers.The Lewy Body with Dementia Association convened a listening session with the US Food and Drug Administration on dementia with Lewy bodies (DLB) and clinical trial design.Gaps include DLB-specific measures, alpha synuclein biomarkers, and coexisting pathologies.DLB clinical trial design should focus on clinical value and disease specificity.

View details for DOI 10.1002/trc2.12375

View details for Web of Science ID 000929340500001

View details for PubMedID 36873923

View details for PubMedCentralID PMC9983146